EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies

Makoto Uchiyama, Kazuo Mishima, Tomoko Yagi, Tatsuya Yoshihara, Takashi Eto, Clemens Muehlan iD, Osamu Togo, Yuichi Inoue iD

Journal of Sleep Research · 2025-02 · 34 (1)

DOI: 10.1111/jsr.14302 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Sleep Research, online erschienen am 08.08.2024. Verfasst von Makoto Uchiyama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Orexin Receptor Antagonists, Pyrrolidines, Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nxera Pharma Japan Co., Ltd, Mochida Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. We report results from the first two randomised, double‐blind clinical studies of daridorexant in Japanese subjects. In the Phase 1 study, daridorexant (10, 25, 50 mg) or placebo were administered in the morning for 4 days in 24 young (mean age 26.9 years) and 24 older (mean age 69.7 years) healthy Japanese adults. Daridorexant reached a peak plasma concentration within 1.0 h across every dose and age group. For all doses, the mean plasma concentration of daridorexant showed a similar change between the age groups. Exposure parameters increased dose‐dependently with minimal/no accumulation upon repeated dosing. The terminal half‐life was ~8 h. In the Phase 2, four‐period, four‐way crossover study, 47 Japanese subjects (mean age 50.4 years) with insomnia disorder were randomised to receive four treatments (daridorexant 10, 25, 50 mg, placebo) during four treatment periods, each consisting of two treatment nights (5–12 day washout between treatment periods). Subjects continued their fourth treatment for 12 further days. A statistically significant dose–response relationship (multiple‐comparison procedure‐modelling, p < 0.0001) was found in the reduction of polysomnography‐measured wake after sleep onset (WASO; primary endpoint) and latency to persistent sleep (secondary endpoint) from baseline to days 1/2. Statistically significant dose–response relationships were also observed for secondary subjective endpoints from baseline to days 1/2 (sWASO, latency to sleep onset). All daridorexant doses were well tolerated, with no treatment discontinuations and no next‐morning residual effects. These results supported further investigation of daridorexant in Japanese patients with insomnia disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orexin Receptor AntagonistsPyrrolidinesSleep Initiation and Maintenance DisordersAdultAgedFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodImidazolesJapanTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Japanesedaridorexantelderlyinsomniaorexin receptor antagonistpharmacokinetics

Substanzen

daridorexantImidazolesOrexin Receptor AntagonistsPyrrolidines

Autor:innen und Institutionen

  • Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan.
  • Tokyo Adachi Hospital, Tokyo, Japan.
  • Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
  • Kurume University School of Medicine, Fukuoka, Japan.
  • SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan.
  • SOUSEIKAI Hakata Clinic, Fukuoka, Japan.

ORCID-Profile: Clemens Muehlan, Yuichi Inoue

Förderung

  • Nxera Pharma Japan Co., Ltd
  • Mochida Pharmaceutical Co., Ltd

Zitieren

APA

Uchiyama, M., Mishima, K., Yagi, T., Yoshihara, T., Eto, T., Muehlan, C., Togo, O., & Inoue, Y. (2025). Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies. Journal of Sleep Research, 34(1). https://doi.org/10.1111/jsr.14302

Vancouver

Uchiyama M, Mishima K, Yagi T, Yoshihara T, Eto T, Muehlan C, et al. Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies. Journal of Sleep Research. 2025;34(1). doi:10.1111/jsr.14302

BibTeX
@article{Uchiyama2025,
  author = {Uchiyama, Makoto and Mishima, Kazuo and Yagi, Tomoko and Yoshihara, Tatsuya and Eto, Takashi and Muehlan, Clemens and Togo, Osamu and Inoue, Yuichi},
  title = {Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies},
  journal = {Journal of Sleep Research},
  year = {2025},
  volume = {34},
  number = {1},
  doi = {10.1111/jsr.14302}
}
Kostenlos starten →